BioTuesdays

Tag - Stifel

Stifel starts Neoleukin Therapeutics at buy; PT $18

Stifel launched coverage of Neoleukin Therapeutics (NASDAQ:NLTX) with a “buy” rating and $18 price target. The stock closed at $14.61 on Jan. 5. Neoleukin is creating next generation immunotherapies primarily for...

Venus-Concept-Logo

Stifel starts Venus Concepts at hold; PT $2.50

Stifel initiated coverage of Venus Concepts (NASDAQ:VERO) with a “hold” rating and price target of $2.50, citing “more work to be done in improving ARTAS,” the company’s robotic hair restoration system. The stock closed...

Syndax Pharma Logo

Stifel starts Syndax Pharmaceuticals at buy; PT $32

Stifel launched coverage of Syndax Pharmaceuticals (NASDAQ:SNDX) with a “buy” rating and price target of $32. The stock closed at $22.79 on Dec. 2. Analyst Konstantinos Aprilakis, M.D., writes that SNDX-5613, the...

Sutra-Biopharma-Logo

Stifel starts Sutro Biopharma at buy; PT $25

Stifel initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and $25 price target. The stock closed at $16.35 on Dec. 2. Sutro is developing XpressCF, a cell-free protein-synthesis platform that...

SQZ-Biotech-Logo

Analysts start SQZ Biotechnologies at buy

Analysts with Stifel and BTIG launched coverage of SQZ Biotechnologies (NYSE:SQZ) with “buy” ratings and price targets of $38 and $40, respectively. The stock closed at $27.62 on Nov. 23. “We believe SQZ’s Cell Squeeze...

AVEO Pharmaceuticals Logo

Stifel starts AVEO Pharma at buy; PT $9

Stifel initiated coverage of AVEO Pharmaceuticals (NASDAQ:AVEO) with a “buy” rating and price target of $9. The stock closed at $5.66 on Nov. 6. AVEO is focused on the development and commercialization of targeted...

Orthofix Logo

Stifel starts Orthofix Medical at buy; PT $39

Stifel launched coverage of Orthofix Medical (NASDAQ:OFIX) with a “buy” rating and price target of $39. The stock closed at $34.05 on Oct. 19. Orthofix is focused on providing medical devices, operating through the...

Alphatec Spine Logo

Stifel starts Alphatec at buy; PT $13

Stifel initiated coverage of Alphatec Holdings (NASDAQ:ATEC) with a “buy” rating and $13 price target. The stock closed at $9.88 on Oct. 19. Alphatec engages in design, development, and marketing of spinal fusion...

SeaSpine Holdings

Stifel starts SeaSpine at buy; PT $22

Stifel launched coverage of SeaSpine Holdings (NASDAQ:SPNE) with a “buy” rating and price target of $22. The stock closed at $14.97 on Oct. 19. “After several years of uneven performance post the 2015 spin-out from...

Nurix Logo

Stifel starts Nurix Therapeutics at buy; PT $34

Stifel initiated coverage of Nurix Therapeutics (NASDAQ:NRIX) with a “buy” rating and $34 price target. The stock closed at $27 on Aug. 17. Nurix is a soon-to-be-clinical-stage company focused on the discovery...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.